380381-36-2

Usage

Uses

Used in Organic Synthesis:
2-Dimethylamino-5-iodopyridine is used as a reagent in organic synthesis for the construction of various heterocyclic compounds. Its unique structure and reactivity make it a valuable building block for the preparation of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
2-Dimethylamino-5-iodopyridine is used as a key intermediate in the synthesis of pharmaceuticals. Its unique structure and reactivity contribute to the development of new drugs with improved therapeutic properties.
Used in Agrochemical Industry:
2-Dimethylamino-5-iodopyridine is used as a building block in the synthesis of agrochemicals. Its unique structure and reactivity enable the development of new agrochemicals with enhanced efficacy and selectivity.
Used in Coordination Chemistry:
2-Dimethylamino-5-iodopyridine is used as a ligand in coordination chemistry. Its unique structure and reactivity make it a promising candidate for the development of new coordination compounds with potential applications in various fields.
Used in Catalyst Development:
2-Dimethylamino-5-iodopyridine has been studied for its potential as a catalyst in organic reactions. Its unique structure and reactivity make it a promising candidate for the development of new catalytic systems to improve reaction efficiency and selectivity.

Upstream product

• 20511-12-0 2-amino-5-iodopyridine 
• 74-88-4 methyl iodide 
• 5683-33-0 2-(Dimethylamino)pyridine 
• 280116-78-1 (5-iodo-pyriin-2-yl) methylamine 
• 50-00-0 formaldehyd 

Downstream Products

• 1083329-64-9 5-S-benzylthio-2-N,N-dimethylaminopyridine 
• 1083329-54-7 5-N-benzylamino-2-N,N-dimethylaminopyridine 
• 1083329-09-2 2-N,N-dimethylamino-5-benzyloxypyridine 

Relevant academic research and scientific papers

NOVEL COMPOUND FOR IMAGING TAU PROTEIN ACCUMULATED IN THE BRAIN

The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof. wherein: R1 and R2 are each separately selected from the group consisting of hydrog

KI-VO(acac)2-H2O2-acoh, A new iodinating system for selective iodination at C-5 position of activated pyrimidinediones: A combined experimental and density functional study

KI-VO(acac)2-H2O2 in aqueous ethanolic medium with acetic acid as additive has been found to iodinate pyrimidinediones and aromatic amines. The methodology is mild, efficient, and environmentally benign. Density functional theory-based reactivity parameters support the experimentally observed reactivity of pyrimidinedione derivatives.

2-ARYLBENZOTHIOPHENE DERIVATIVES OR PHARCEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARCEUTICAL COMPOSITION FOR THE DIAGNOSIS OR TREATMENT OF DEGENERATIVE BRAIN DISEASE CONTAINING THE SAME AS ACTIVE INGREDIENT

2-arylbenzothiophene derivatives or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as an active ingredient. Since the 2-arylbenzothiophene derivatives of Formula 1 have a relatively high binding affinity for β-amyloid, they can be used as diagnostic reagents for diagnosing Alzheimer's disease at an early stage by non-invasive techniques when they are labeled with radioisotopes: wherein R1-R4, V, W, X, Y and Z are as defined in the Detailed Descript of the specification. Further, when the pharmaceutical composition containing the 2-arylbenzothiophene derivative binds with a low-molecular weight β-amyloid peptide binding compound, generation of malignant high-molecular weight β-amyloid deposits is minimized. Accordingly, the pharmaceutical composition can be used as a therapeutic agent of degenerative brain disease such as Alzheimer's disease.

A simple Cu-catalyzed coupling approach to substituted 3-pyridinol and 5-pyrimidinol antioxidants

(Chemical Equation Presented) A convenient approach to 3-pyridinols and 5-pyrimidinols via a two-step Cu-catalyzed benzyloxylation/catalytic hydrogenation sequence is presented. The corresponding 3-pyridinamines and 5-pyrimidinamines can be prepared in an analogous sequence utilizing benzylamine in lieu of benzyl alcohol. The radical-scavenging ability of these derivatives are preliminarily explored and reveal that the increased acidities of the pyridinols and pyrimidinols render them susceptible to more significant kinetic solvent effects when compared to phenols.

3-‘4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL!-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES

Disclosed compounds of formula (I), which inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Ophthalmic compositions for treating ocular hypertension

This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relate